As Expected, Nasdaq to Delist Tripos 'Shell' From Stock Market | GenomeWeb
NEW YORK (GenomeWeb News) — As expected, the Nasdaq Stock Market said it plans to file a petition with the US Securities and Exchange Commission to delist Tripos, the market said today.
 
Nasdaq said the delisting will become effective 10 days after the filing. Tripos has not traded on the Nasdaq since July 6, when the market suspended its stock.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.